Back to top
more

Cassava Sciences (SAVA)

(Delayed Data from NSDQ)

$22.14 USD

22.14
954,527

-0.01 (-0.05%)

Updated May 1, 2024 04:00 PM ET

After-Market: $22.10 -0.04 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SAVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cassava Sciences, Inc. [SAVA]

Reports for Purchase

Showing records 101 - 117 ( 117 total )

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 101

07/20/2021

Company Report

Pages: 6

In ADAS-Cog, Simufilam May Take the Road Less Traveled in Alzheimer’s; Raising PT to $124 From $97

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 102

07/01/2021

Company Report

Pages: 24

Comprehensive Technical and Fundamental Analysis for SAVA.

Provider: Stock Traders Daily

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 103

04/22/2021

Company Report

Pages: 5

An HCW Top Pick Showing Momentum in 1Q21; Reiterate Buy and $97 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 104

03/24/2021

Company Report

Pages: 6

Expecting Simufilam’s Strong Momentum to Continue Through 2021; Reiterate Buy and $97 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 105

02/23/2021

Company Report

Pages: 7

FDA Alignment With Phase 3 Strategy Clears the Pivotal Pathway for Simufilam; Reiterate Buy and Raise PT to $97

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 106

02/16/2021

Company Report

Pages: 6

Simufilam Results Point to Potential for Lasting Benefits in Alzheimer’s

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 107

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 108

11/05/2020

Company Report

Pages: 5

New Data at CTAD Could Garner Increased Interest in Sumifilam; Reiterate Buy Rating and $20 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 109

09/23/2020

Company Report

Pages: 5

Final Analysis of Sumifilam Phase 2b Is Transformative; Upgrading to Buy From Neutral With a $20 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 110

05/18/2020

Company Report

Pages: 5

Top-line PTI-125 Phase 2b Failure Reminds Us Why Alzheimer''s Is Hard; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 111

05/08/2020

Company Report

Pages: 4

Stage Set for PTI-125 to Unfold in 2020; Reit Buy and Raise PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 112

03/27/2020

Company Report

Pages: 4

Expecting PTI-125’s Momentum to Keep Going in 2020; Reit Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 113

03/26/2020

Company Report

Pages: 4

Further Advancement of PTI-125 in Alzheimer’s Disease Continues to Be Intriguing

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 114

12/06/2019

Daily Note

Pages: 3

Data at CTAD Supports PTI-125''s Potential to Slow Down Alzheimer''s Progression

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 115

09/13/2019

Company Report

Pages: 3

Positive Phase 2a Clinical Results With PTI-125 in Alzheimer’s Patients: Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 116

08/16/2019

Company Report

Pages: 4

2Q19 Recap and What to Look for in 2H19: Reiterate Buy and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 117

08/01/2019

Company Report

Pages: 20

Acquiring a Taste for Cassava; Initiating With a Buy and $3 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 50.00

Research Provided by a Third Party